Managed Access Programs for CTL019, Tisagenlecleucel
Expanded access registry listing of Novartis managed access programs for tisagenlecleucel (CTL019), a CD19 CAR-T cell therapy, for patients with lymphoma or leukemia who cannot use a trial or the approved product. No efficacy or safety data are reported.
| Status | Available |
|---|
Results Summary
No results have been posted to ClinicalTrials.gov or published for this expanded access record, and the registry lists no outcome measures. The record describes three Novartis managed access programs for tisagenlecleucel (out-of-specification leukapheresis or manufactured product, reinfusion for approved indications, and off-label indications); it reports no patient numbers, efficacy results or adverse events.
Design Implications
This record is an access listing, not a study, so it supports no efficacy, safety, dose or delivery lesson for tisagenlecleucel or CD19 CAR-T design. It shows only that demand exists for CD19 CAR-T cell therapy beyond its approved indications and trial eligibility, including reinfusion and use of product that failed manufacturing release specifications. Agents designing CAR-T products should take outcome evidence from the interventional trials of tisagenlecleucel, not from this record.
Rationale
Tisagenlecleucel (CTL019) is an autologous T-cell product engineered with a lentiviral vector to express a chimeric antigen receptor against CD19, a surface protein on normal and malignant B cells. Binding CD19 activates the T cells to kill CD19-positive lymphoma and leukemia cells. These managed access programs extend the product to patients with serious B-cell malignancies who have no satisfactory alternative and cannot enrol in a trial: out-of-specification leukapheresis or manufactured product, reinfusion for approved indications, and off-label indications.
Limitations
Expanded access program listing with no enrolment data, no registered outcome measures, no posted results and no linked publications. Eligible diseases are stated only as lymphoma, leukemia and off-label indications, so no population or outcome can be inferred from it.
Registry record
The purpose of this registration is to list Managed Access Programs (MAPs) related to CTL019, Tisagenlecleucel
| Official Title | Managed Access Programs for CTL019, Tisagenlecleucel |
|---|---|
| Keywords | MAP, Expanded Access, Lymphoma, Leukemia, Off-label indications |
| Registry Last Updated | 2026-04-23 |
| Minimum Age | 0 Days |
| Modalities | cell_therapy |
| Intervention Names | CTL019, tisagenlecleucel |
| Has Results | No |
| Intervention Types | biological |
| Study Type | Expanded Access |
| Healthy Volunteers | No |
| Condition Terms | Lymphoma, Leukemia, Off-label Indications |
| Lead Sponsor Class | Industry |
| Eligibility Sex | All |
Eligibility Criteria
Inclusion Criteria:
An independent request was received from a licensed physician. The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment.
The patient is not eligible or able to enrol in a clinical trial or continue participation in such trial.
There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.
The patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable).
Provision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program.
Managed Access provision is allowed per local laws/regulations.
Identifiers & revision
clinicaltrials NCT03601442
